Open AccessSafety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years’ Experience from the PATRO Children Study
Author(s) -
Roland Pfäffle,
Martin Bidlingmaier,
Ilonka KreitschmannAndermahr,
Christof Land,
Carl Joachim Partsch,
Karl Otfried Schwab,
Heide Sommer,
Philippe Backeljauw,
Shankar Kanumakala,
Sandro Loche,
Hichem Zouater,
Christian J. Strasburger
Publication year - 2020
Publication title -
hormone research in paediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.816
H-Index - 89
eISSN - 1663-2826
pISSN - 1663-2818
DOI - 10.1159/000508190
Subject(s) - medicine , adverse effect , biosimilar , pediatrics , population , gastroenterology , environmental health
Omnitrope® was approved as a biosimilar recombinant human growth hormone (rhGH) in 2006.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom